Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

74.57 USD +0.03 (+0.04%)
Official Closing Price Updated: 7:56 PM EST, Feb 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abira
LYNPARZA Reduced Risk of Death by 31% for Men with BRCA1/2 or ATM-Mutated mCRPC Who Progressed Following Enzalutamide or Abiraterone in Ph 3 Trial 
From Business Wire News Releases
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020 
From Business Wire News Releases
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma 
From Business Wire News Releases
LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
LYNPARZA® Improved Median Progression-Free Survival to Over Four and a Half Years for Patients with BRCA-Mutated Advanced Ovarian Cancer 
From Business Wire News Releases
Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020
Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020 
From Business Wire News Releases
BRENZYS® (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis
From PR Newswire
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference 
From Business Wire News Releases
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations. 
From Business Wire News Releases
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference 
From Business Wire News Releases
Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Merck Announces Positive Topline Results from Two Phase 3 Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine 
From Business Wire News Releases
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
Merck’s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo in Patients with Refractory or Unexplained Chronic Cough 
From Business Wire News Releases
Biopharma Leaders Unite to Stand With Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
From GlobeNewswire News Releases
Biopharma Leaders Unite To Stand With Science
Biopharma leaders unite to stand with science. 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference 
From Business Wire News Releases
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care 
From Business Wire News Releases
TriRx Pharmaceutical Services acquires MSD Animal Health manufacturing site located in Segré-en Anjou Bleu, France including long-term supply agreement
TriRx Pharmaceutical Services, a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical market, today announced that it has finalized an agreement with MSD... 
From PR Newswire
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Editorial Projecting Significant Growth for Global Brain Tumor Therapeutics Sector
From InvestorBrandNetwork
Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan 
From Business Wire News Releases
Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers
From ACN Newswire
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Me
KEYTRUDA® in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival in Esophageal Cancer 
From Business Wire News Releases
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
From ACN Newswire
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
From GlobeNewswire News Releases
Merck Animal Health Completes Acquisition of IdentiGEN
Merck Animal Health Completes Acquisition of IdentiGEN 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account